Biogen, Incorporated

Biogen Idec Ma Inc.

Apoxis S.a.

Other

The General Hospital Corporation

Dana-farber-cancer Institute Inc.

Curagen Corporation

Catherine A Hession

Christopher D Benjamin

Roy R Lobb

Susan E Goelz

Margaret D Rosa

Michele Sanicola-Nadel

Laurelee Osborn

Barbara P Wallner

Richard L Cate

Jurg Tschopp

Antonin De Fougerolles

Victor E Kotelianski

Linda C Burkly

Joseph V Bonventre

Dane S Worley

Cynthia A Green

John P Carulli

Timothy Alan Springer

Michael L Dustin

Adrian Whitty

Takaharu Ichimura

Richard Tizard

Robert Mattaliano

Richard Tizard, Jr

Henry Wei

John Carulli

The present invention provides novel isolated BLAA polynucleotides and the membrane-associated or secreted polypeptides encoded by the BLAA polynucleotides. Also provided are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant or fragment of the BLAA polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BLAA polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

Polynucleotides encoding members of the human B lymphocyte activation antigen B7 family and polypeptides encoded thereby

Embodiments of the present invention encompass novel receptors of the TNF family. In particular, embodiments of the invention encompass TNF Receptor in the BRAIN (TRAIN) and isolated antibodies that bind to the same. In some embodiments, isolated antibodies that bind to TRAIN are useful in regulating cell differentiation, death, and survival. Other embodiments of the invention encompass pharmaceutical compositions comprising antibodies that bind to human TRAIN.

Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor

Novel receptor in the TNF family: TRAIN-receptor.

TRAIN-R: a cysteine-rich member of the TNF-receptor family

The present invention relates to novel receptors in the TNF family. A novel receptor has been identified, referred to herein as TRAIN. The invention relates to DNA sequences encoding TRAIN receptors. The invention also contemplates recombinant DNAs comprising a sequence encoding TRAIN receptors or fragments thereof, as well as hosts with stably integrated TRAIN-R sequences introduced into their genome, or possessing episomal elements.

Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family

Disclosed are cis-acting regulatory elements from a KIM-1 gene. The elements can be used to direct the expression of operably linked sequences in renal tissue.

Renal regulatory elements and methods of use thereof

Nucleotide and amino acid sequences are provided for compounds which promote tissue growth, as well as methods for modulating tissue growth, for imaging tissues and organs, and for treating patients.

Antibodies to Ret and RetL3

The invention relates to antibodies which specifically bind to the gc chain of cytokine receptors, as well as to cell lines which produce such antibodies, pharmaceutical compositions, and methods of treating immunological diseases by treating patients with such antibodies.

Common gamma chain blocking agents

Nucleotide and amino acid sequences are provided for compounds which promote tissue growth, as well as methods for modulating tissue growth, for imaging tissues and organs, and for treating patients. Isolated nucleic acid and amino acid sequences for Ret ligands are disclosed. Ret ligands encoded by the isolated nucleic acid sequences of the invention have a hydrophobic N-terminal signal sequence, a hydrophobic C-terminal sequence and a phosphatidylinositol glycan linkage motif. Vectors and host cells that include Ret ligands encoded by the isolated nucleic acid sequences of the invention are also disclosed.

Ret ligand (RetL) for stimulating neutral and renal growth

Proteins which are upregulated in injured or regenerating tissues, as well as the DNA encoding these proteins, are disclosed, as well as therapeutic compositions and methods of treatment encompassing these compounds.

Kidney injury-related molecules

An isolated BLAA polynucleotide and the membrane-associated or secreted polypeptide encoded by the BLAA polynucleotide are disclosed. Also disclosed are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant or fragment of the BLAA polypeptide, polynucleotide or antibody. Also disclosed are nucleic acid vectors and host cells containing the nucleic acid sequence of the invention.

Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same

Common gamma chain monoclonal antibody blocking agents

VCAM fusion proteins capable of binding to VLA4, and DNA molecules coding on these fusions.

VCAM fusion proteins and DNA coding therefor

VCAM1 polypeptides and VCAM11/ICAM fusion proteins are disclosed.

Vascular cell adhesion molecule (VCAM) polypeptides

DNA sequences encoding endothelial cell-leukocyte adhesion molecules ELAMs, methods for producing such molecules, and ELAMs (including the specific molecules ELAM1 and VLAM1 and 1b) essentially free of normally associated animal proteins are disclosed. DNA sequences encoding molecules involved in leukocyte adhesion (MILAs), methods for producing such molecules and MILAs (including the specific molecule, CDX) essentially free of normally associated animal proteins are also disclosed. Antibody preparations which are reactive for MILAs and also disclosed. Methods for identifying molecules which inhibit binding of leukocytes to endothelial cells, methods for inhibiting leukocyte binding to endothelial cells, and methods for detecting acute inflammation are disclosed.

Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules

A phosphatidylinositol (PI)-linked form of the LFA-3 polypeptide, which binds to CD2 molecules on the surface of T lymphocytes, in provided. Soluble polypeptides derived from the native sequence are also disclosed. DNA sequences, vectors, and transformed unicellular hosts useful for making these polypeptides are provided. Methods for using the LFA-3 polypeptides in therapy an diagnosis are described.

Growing community of inventors

South Weymouth, MA, United States of America

Catherine A Hession